Antiretroviral treatment indications and adherence to the German-Austrian treatment initiation guidelines in the German ClinSurv HIV Cohort between 1999 and 2016.
Adherence
Antiretroviral therapy
HIV
START
Treatment guidelines
Journal
Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
11
09
2018
accepted:
03
11
2018
pubmed:
11
11
2018
medline:
6
7
2019
entrez:
11
11
2018
Statut:
ppublish
Résumé
The aim of the study was to assess guideline adherence to combined antiretroviral therapy (ART) in the German ClinSurv HIV Cohort and the real-life impact of the Strategic Timing of Antiretroviral Therapy (START) study, to identify patients not treated as recommended by new guidelines. We used data from the multicenter ClinSurv cohort of the Robert-Koch-Institute (RKI) between 1999 and 2016. Inclusion criteria were people living with HIV/AIDS, ≥ 18 years of age and cART naïve at the first visit (FV). Adherence was defined as starting cART within 6 months of crossing the CD4 11,817 patients met the inclusion criteria. We observed an overall adherence rate of 60%, in patients with treatment indication who started cART timely between 2002 and 2015. Adherence rate increased constantly, demonstrating a potential increase in patients, with treatment indication, starting cART within 6 months of presentation from 55% in 2008 to 94% in 2015. Patients reporting injection drug use (OR 2.18, 95% CI 1.70-2.95) and patients between 18 years and 39 years of age at the time of their first visit (OR 2.89, 95% CI 1.35-6.18) were identified as risk groups associated with non-adherence. The majority of patients below the CD4
Identifiants
pubmed: 30414065
doi: 10.1007/s15010-018-1248-8
pii: 10.1007/s15010-018-1248-8
doi:
Substances chimiques
Anti-Retroviral Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
247-255Subventions
Organisme : Deutsches Zentrum für Infektionsforschung
ID : NCT02149004
Commentaires et corrections
Type : ErratumIn
Références
J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Mar 1;20(3):220-7
pubmed: 10077169
MMW Fortschr Med. 2000 Mar 13;142 Suppl 1:45-9
pubmed: 10863311
Dtsch Med Wochenschr. 2003 May 9;128 Suppl 1:S7-18
pubmed: 12736863
J Infect Dis. 2006 Jul 1;194(1):11-9
pubmed: 16741877
J Acquir Immune Defic Syndr. 2006 Dec 1;43(4):451-7
pubmed: 16980906
Med Care. 2006 Nov;44(11):990-7
pubmed: 17063130
J Acquir Immune Defic Syndr. 2007 Nov 1;46 Suppl 2:S64-71
pubmed: 18089986
HIV Med. 2011 May;12(5):269-78
pubmed: 20955355
J AIDS HIV Res. 2011 Mar;3(3):63-70
pubmed: 21866279
BMJ. 2011 Oct 11;343:d6016
pubmed: 21990260
Curr Opin HIV AIDS. 2011 Dec;6 Suppl 1:S3-11
pubmed: 22156777
Lancet. 2012 Dec 15;380(9859):2163-96
pubmed: 23245607
Lancet. 2012 Dec 15;380(9859):2197-223
pubmed: 23245608
Lancet Infect Dis. 2014 Apr;14(4):281-90
pubmed: 24602844
Ophthalmic Physiol Opt. 2014 Sep;34(5):502-8
pubmed: 24697967
Epidemiology. 2014 May;25(3):406-17
pubmed: 24713880
BMC Public Health. 2015 Mar 17;15:252
pubmed: 25848706
BMC Infect Dis. 2015 Apr 18;15:193
pubmed: 25927573
N Engl J Med. 2015 Aug 27;373(9):795-807
pubmed: 26192873
N Engl J Med. 2015 Aug 27;373(9):808-22
pubmed: 26193126
AIDS. 2015 Sep 10;29(14):1855-62
pubmed: 26372391
Clin Infect Dis. 2016 Mar 1;62(5):655-663
pubmed: 26620652
AIDS Care. 2015;27(12):1429-38
pubmed: 26641139
Lancet HIV. 2017 Aug;4(8):e349-e356
pubmed: 28501495
Clin Microbiol Infect. 2019 Feb;25(2):253.e1-253.e4
pubmed: 30315957